FILING ANALYSIS · FRIDAY, NOVEMBER 13
Inhibrx Biosciences, Inc. INBX — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $38.7 million, or $2.46 per share, and had cash and cash equivalents of $199.5 million as of September 30, 2026, with no significant quantified surprises in the earnings report.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →